Search filters
Filters
Clear All

Phase

  • 12
  • 39
  • 2
  • 26
  • 1
  • 16
  • 1
  • 251
  • 352
  • 262
  • 4
  • 25
  • 323

Found 352 oncology trials

A listing of oncology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 02423: Phase 2 study of cevostamab consolidation following BCMA CAR T cell therapy for relapsed/refractory multiple myeloma

99 years or below
All genders
Please refer to the protocol, Section 2 (Objectives and Endpoints) Please refer to the protocol, Section 2 (Objectives and Endpoints) Please refer to the protocol, Section 2 (Objectives and Endpoints)
Learn More

UPCC 17423: An open-label phase II study to investigate the efficacy, safety, and pharmacokinetics of tirabrutinib in patients with Primary Central Nervous System Lymphoma (PCNSL)

99 years or below
All genders
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment …
Learn More

UPCC 25523: ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects with Leiomyosarcoma (ARGSARC): A Randomized, Double-Blind, Multi-Center Phase 3 Trial

99 years or below
All genders
This is a global, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 trial that will compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline. We would like to rely on WCG as the IRB of record for this study.
Learn More

UPCC 50423: A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants with Newly Diagnosed Multiple Myeloma Who

99 years or below
All genders
The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT). We would like to …
Learn More

UPCC 16323: Neoadjuvant/Phase 1 Study of CD40 Agonist (LVGN7409) and PD-1 Inhibitor (LVGN3616) in Patients with Resectable HPV-Negative Mucosal Head/Neck Squamous Cell Carcinoma (HNSCC)

99 years or below
All genders
Please refer to Protocol Section 3 (Study Objectives and Endpoints). Please refer to Protocol Section 3 (Study Objectives and Endpoints). Please refer to Protocol Section 3 (Study Objectives and Endpoints).
Learn More

UPCC 36423: Resilience in Older Adults with Leukemia Receiving Initial Treatment: the ROAR-1 Study

99 years or below
All genders
The purpose of this study is understand changes in cognition, physical abilities, and quality of life of individuals receiving venetoclax-based chemotherapy.
Learn More

UPCC 29421: Administration of HIV-specific T cells to HIV+ Patients Receiving High Dose Chemotherapy Followed by Autologous Stem Cell Rescue -Auto-RESIST

99 years or below
All genders
Were doing this study to see if a type of cells called HST-NEETs can help the body fight HIV. HST-NEETs are cells made from immune cells that have been treated and grown in a lab. This is a phase 2 study.
Learn More

UPCC 43423: A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

99 years or below
All genders
This is an open-label, multicenter, Phase 1b/2 study to determine the safety and tolerability of IMGN632 and assess the antileukemia activity of IMGN632 when administered in combination with azacitidine and/or venetoclax in participants with relapsed and frontline CD123-positive AML. We would like to rely on Advarra IRB as the IRB …
Learn More

UPCC 24223: AIRPanc - A Phase 2 , Open-Label, Multicenter, Randomized Study Evaluating neoadjuvant therapy targeting the Adenosine immunosuppressive pathway in combination with Immune checkpoint blockade and Radiation Therapy in Patients with advanced

99 years or below
All genders
Please refer to Protocol Section 2 (Study Objectives). Please refer to Protocol Section 15.1 (Study Design/Endpoints). Please refer to Protocol Section 15.1 (Study Design/Endpoints).
Learn More

UPCC 13419: An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)

99 years or below
All genders
The purpose of this study is to evaluate the safety, recommended dose, antitumor activity, and pharmacokinetics of JCAR017 in subjects with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The safety of JCAR017 in subjects who are receiving concurrent ibrutinib will also be evaluated.
Learn More
301 - 310 of 352